ImmuCell/$ICCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmuCell
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Ticker
$ICCC
Sector
Primary listing
Employees
73
Headquarters
Website
ImmuCell Metrics
BasicAdvanced
$90m
-
-$0.07
-
-
Price and volume
Market cap
$90m
52-week high
$10.25
52-week low
$4.52
Average daily volume
31k
Financial strength
Current ratio
4.82
Quick ratio
2.43
Long term debt to equity
37.962
Total debt to equity
43.856
Interest coverage (TTM)
6.69%
Profitability
EBITDA (TTM)
5.883
Gross margin (TTM)
42.59%
Net profit margin (TTM)
-1.82%
Operating margin (TTM)
11.03%
Effective tax rate (TTM)
-4.24%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
4.60%
Return on equity (TTM)
-1.88%
Valuation
Price to revenue (TTM)
2.994
Price to book
3.08
Price to tangible book (TTM)
3.09
Price to free cash flow (TTM)
26.545
Free cash flow yield (TTM)
3.77%
Free cash flow per share (TTM)
0.373
Growth
Revenue change (TTM)
9.64%
Earnings per share change (TTM)
113.93%
3-year revenue growth (CAGR)
23.18%
10-year revenue growth (CAGR)
11.46%
3-year earnings per share growth (CAGR)
-53.68%
10-year earnings per share growth (CAGR)
-14.94%
ImmuCell News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmuCell stock?
ImmuCell (ICCC) has a market cap of $90M as of May 19, 2026.
What is the P/E ratio for ImmuCell stock?
The price to earnings (P/E) ratio for ImmuCell (ICCC) stock is 0 as of May 19, 2026.
Does ImmuCell stock pay dividends?
No, ImmuCell (ICCC) stock does not pay dividends to its shareholders as of May 19, 2026.
When is the next ImmuCell dividend payment date?
ImmuCell (ICCC) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmuCell?
ImmuCell (ICCC) does not currently have a Beta indicator.